PA8813701A1 - Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica

Info

Publication number
PA8813701A1
PA8813701A1 PA20098813701A PA8813701A PA8813701A1 PA 8813701 A1 PA8813701 A1 PA 8813701A1 PA 20098813701 A PA20098813701 A PA 20098813701A PA 8813701 A PA8813701 A PA 8813701A PA 8813701 A1 PA8813701 A1 PA 8813701A1
Authority
PA
Panama
Prior art keywords
group
alquil
nr6r7
atom
rent
Prior art date
Application number
PA20098813701A
Other languages
English (en)
Inventor
Alain Braun
Oliver Crespin
Claudie Namane
Eric Nicolai
Francois Pacquet
Cecile Pascal
Christophe Philippo
Oliver Venier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0800429A external-priority patent/FR2926817B1/fr
Priority claimed from FR0804521A external-priority patent/FR2934858B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8813701A1 publication Critical patent/PA8813701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A LOS COMPUESTOS QUE RESPONDEN A LA FÓRMULA (I): EN LA QUE A REPRESENTA UN ENLACE, UN ÁTOMO DE OXÍGENO O UN GRUPO -O-CH2-; AR, REPRESENTA UN GRUPO FENILO O HETEROARILO ; AR2 REPRESENTA UN GRUPO FENILO, HETEROARILO O HETEROCICLOALQUILO ; R1A,B,C Y R2A,B,C REPRESENTAN UN ÁTOMO DE HIDRÓGENO O DE HÁLOGENO O UN GRUPO ALQUILO, CICLOALQUILO, -ALQUIL-CICLOALQUILO SUSTITUIDO OPCIONALMENTE CON UNO O VARIOS ÁTOMOS DE HALÓGENO, -OR5 (HIDROXI O ALCOXI), HIDROXI-ALQUILO, ALCOXI-ALQUILO, ALCOXI-ALCOXI, HALÓGENOALQUILO, -O-HALÓGENOALQUILO, OXO, -CO-ALQUILO, -CO-ALQUILO-NR6R7, -CO-HALÓGENOALQUILO, -COOR5, ALQUI-COOR5, -O-ALQUIL-COOR5, -SO2-ALQUIL-NR6R7 -SO2-HALÓGENOALQUILO, ALQUIL-SO2-ALQUILO, -SO2-NR6R7, -SO2-ALQUIL-O-ALQUIL-OR5, -CONR6R7, -ALQUIL-CONR6R7 O -O-ALQUIL-NR6R7, O R1A, R1B, R1C ESTÁN UNIDOS RESPECTIVAMENTE A R2A, R2B, R2C Y AL ÁTOMO DE CARBONO AL QUE ESTÁN UNIDOS Y REPRESENTAN -O-ALQUIL-O- ; R3 REPRESENTA UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALQUILO, R4 REPRESENTA UN ÁTOMO DE HIDRÓGENO O DE HALÓGENO O UN GRUPO CIANO, -OR5, HIDROXI-ALQUILO, -COOR5, -NR6R7, -CONR6R7, -SO2-ALQUILO O -SO2-NR6R7, -NR6-COOR5, -NR6- COR5, -CO-NR6-ALQUIL-OR5 ; R5, R6 Y R7 REPRESENTAN UN ÁTOMO DE HIDRÓGENO, UN GRUPO ALQUILO O -ALQUIL-FENILO, Y R8 REPRESENTA UN ÁTOMO DE HIDRÓGENO, UN GRUPO -SO2-ALQUILO O UN GRUPO DE FÓRMULA -B-HET, EN LA QUE B PUEDE ESTAR AUSENTE O REPRESENTAR UN ENLACE, UN ÁTOMO DE OXÍGENO O UN GRUPO -CO- O -SO2-(CH2)N CON N IGUAL A 0, 1 Ó 2 Y EN LA QUE HET REPRESENTA UN HETEROARILO O UN HETEROCICLOALQUILO SUSTITUIDO OPCIONALMENTE CON GRUPOS ALQUILOS, -SO2-ALQUILOS Y -COOR5. PROCEDIMIENTO DE PREPARACIÓN Y APLICACIÓN EN TERAPÉUTICA.
PA20098813701A 2008-01-28 2009-01-27 Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica PA8813701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800429A FR2926817B1 (fr) 2008-01-28 2008-01-28 Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR0804521A FR2934858B1 (fr) 2008-08-08 2008-08-08 Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PA8813701A1 true PA8813701A1 (es) 2009-09-17

Family

ID=41037885

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098813701A PA8813701A1 (es) 2008-01-28 2009-01-27 Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica

Country Status (24)

Country Link
US (2) US8211892B2 (es)
EP (1) EP2238126B1 (es)
JP (1) JP2011510919A (es)
KR (1) KR20100111308A (es)
CN (1) CN101981026A (es)
AR (1) AR070255A1 (es)
AU (1) AU2009224546B2 (es)
BR (1) BRPI0906567A2 (es)
CA (1) CA2713367A1 (es)
CL (1) CL2009000173A1 (es)
CO (1) CO6290672A2 (es)
CR (1) CR11596A (es)
DO (1) DOP2010000230A (es)
EA (1) EA201070895A1 (es)
EC (1) ECSP10010368A (es)
IL (1) IL207195A (es)
MA (1) MA32098B1 (es)
MX (1) MX2010008290A (es)
NI (1) NI201000130A (es)
PA (1) PA8813701A1 (es)
PE (1) PE20091323A1 (es)
TW (1) TW200936136A (es)
UY (1) UY31616A1 (es)
WO (1) WO2009112691A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2948369B1 (fr) * 2009-07-27 2013-04-12 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
EP2500345B1 (en) * 2009-11-11 2015-01-28 Sumitomo Dainippon Pharma Co., Ltd. 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
WO2011078101A1 (ja) * 2009-12-22 2011-06-30 塩野義製薬株式会社 アダマンタンアミン誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5812295B2 (ja) 2010-08-09 2015-11-11 塩野義製薬株式会社 アミノアダマンタンカルバメート誘導体の製造方法
KR20130102065A (ko) 2010-09-03 2013-09-16 다이닛본 스미토모 세이야꾸 가부시끼가이샤 고리형 아미드 유도체
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP6043767B2 (ja) * 2014-09-26 2016-12-14 株式会社アステム 番組出力装置、補助情報管理サーバ、番組と補助情報の出力方法、及びプログラム
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN109956958B (zh) * 2019-04-02 2020-06-16 河北合佳医药科技集团股份有限公司 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
GB0505541D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
TW200811158A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application
TW200811170A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
JP5223864B2 (ja) * 2007-06-27 2013-06-26 大正製薬株式会社 １１β−ＨＳＤ１阻害活性を有する化合物
WO2009020140A1 (ja) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
TW200936136A (en) 2009-09-01
MA32098B1 (fr) 2011-02-01
US8530657B2 (en) 2013-09-10
CL2009000173A1 (es) 2010-02-12
CA2713367A1 (fr) 2009-09-17
AU2009224546A1 (en) 2009-09-17
JP2011510919A (ja) 2011-04-07
NI201000130A (es) 2010-12-17
US20110009391A1 (en) 2011-01-13
AR070255A1 (es) 2010-03-25
CN101981026A (zh) 2011-02-23
MX2010008290A (es) 2010-08-18
UY31616A1 (es) 2009-08-31
IL207195A (en) 2013-12-31
WO2009112691A3 (fr) 2010-01-07
EA201070895A1 (ru) 2011-04-29
KR20100111308A (ko) 2010-10-14
CR11596A (es) 2010-09-13
CO6290672A2 (es) 2011-06-20
ECSP10010368A (es) 2010-08-31
PE20091323A1 (es) 2009-09-26
EP2238126B1 (fr) 2014-11-05
US8211892B2 (en) 2012-07-03
DOP2010000230A (es) 2010-08-31
US20120245148A1 (en) 2012-09-27
AU2009224546B2 (en) 2014-01-30
BRPI0906567A2 (pt) 2015-07-07
IL207195A0 (en) 2010-12-30
EP2238126A2 (fr) 2010-10-13
WO2009112691A2 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
PA8813701A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
PA8785301A1 (es) "nuevos indazoles sustituidos, su preparacion y su utilizacion en terapeutica
BR112013009789A2 (pt) inibidores do vírus da hepatite c
GT200800211A (es) Derivados de dihidropirazolopirimidinona
ECSP10010060A (es) Derivados de pirazol sustituídos
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
CY1113764T1 (el) Βενζοϊκου οξεος (1-φαινυλ-2-πυριδιν-4-υλ) αιθυλ εστερες ως αναστολεις φωσφοδιεστερασης
HN2009000502A (es) DERIVADOS DE 2- ARIL-6-FENIL-IMIDAZO[ 1,2-a] PIRIDINAS SU PREPARACION Y SU APLICACION EN TERAPEUTICA
CR20110484A (es) Nuevos derivados de benzotiazepinas su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR073774A1 (es) Compuestos antibioticos oxazolidinona triciclicos
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
ECSP12011760A (es) Estabilizante de amina estéricamente inhibida
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
AR075777A1 (es) Derivados de benzotiazina, su preparacion y aplicacion como farmacos para la inhibicion de 11beta-hidroxiesteroide deshidrogenasa tipo i (11betahsd1)
ATE534708T1 (de) Pigmentzusammensetzung auf basis von c.i. pigment yellow 191
AR070438A1 (es) Derivados de 3- aminoalquil -1,3- dihidro -2h indol-2- ona su preparacion y su aplicacion en terapeutica
BRPI0815455B8 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
AR077425A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
IL209111A0 (en) Time temperature indicator comprising indolenin based spiropyrans containing a n-acetylamido or n-acetylester side chain
AR077499A1 (es) Derivados de urea de tetrahidroquinoxalina su preparacion y su aplicacion en terapia